financetom
Business
financetom
/
Business
/
Strategic Resources Signs Iron Ore Supply, Offtake Agreements with Javelin Global Commodities
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Strategic Resources Signs Iron Ore Supply, Offtake Agreements with Javelin Global Commodities
Nov 25, 2024 5:34 AM

08:29 AM EST, 11/25/2024 (MT Newswires) -- Strategic Resources said (SR.V) Monday that it signed iron ore supply and offtake agreements with Javelin Global Commodities (SG) PTE, a subsidiary of Javelin Global Commodities.

Javelin also agreed to provide a secured working capital facility of up to US$150 million for up to three years to support the operations of Strategic's high purity iron pelletizer facility at Port Saguenay in Quebec.

Under the terms, Strategic will procure four million tonnes of direct reduction (DR) grade iron ore concentrate and sell up to four million tonnes a year of DR grade iron pellets from the facility.

The agreement also includes a ten-year contract from the completion of construction with Strategic having an option to terminate, including the right to terminate after seven years from the commencement of production of the iron ore products.

"Javelin is an outstanding long-term partner to work with given their demonstrated track record in the seaborne iron concentrate and iron pellet markets and provides another major international sponsor for the project," Strategic CEO Sean Cleary said. "The completion of the offtake agreements is a significant milestone for Strategic and puts the company in a position to complete the required next steps over the first three quarters of 2025 as it works towards the start of construction of the high purity iron pellet plant."

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Johnson Controls' Fiscal Q3 Adjusted EPS, Revenue Rise; Initiates Q4 Guidance; Adjusts Full-Year Guidance; Shares Up Pre-Bell
Johnson Controls' Fiscal Q3 Adjusted EPS, Revenue Rise; Initiates Q4 Guidance; Adjusts Full-Year Guidance; Shares Up Pre-Bell
Jul 31, 2024
07:49 AM EDT, 07/31/2024 (MT Newswires) -- Johnson Controls International ( JCI ) reported fiscal Q3 adjusted earnings Wednesday of $1.14 per diluted share, compared with $1.03 a year earlier. Analysts surveyed by Capital IQ expected $1.08. Revenue for the quarter ended June 30 was $7.23 billion, compared with $7.13 billion a year earlier. Analysts surveyed by Capital IQ expected...
What's Going On With Starbucks Stock Wednesday?
What's Going On With Starbucks Stock Wednesday?
Jul 31, 2024
Starbucks Corporation ( SBUX ) shares are trading higher on Wednesday. According to Benzinga Pro, SBUX stock has lost over 25% in the past year. Investors can gain exposure to the stock via Global X Millennial Consumer ETF ( MILN ) and SPDR Select Sector Fund – Consumer Discretionary . Yesterday, the company reported third-quarter results where revenues of $9.1 billion missed the consensus...
Altria posts lower-than-expected quarterly results on muted cigarette demand
Altria posts lower-than-expected quarterly results on muted cigarette demand
Jul 31, 2024
(Reuters) - Altria ( MO ) missed expectations for quarterly revenue and profit on Wednesday, as the tobacco giant contends with persistent weakness in demand for its cigarette brands. Shares of the company, which have risen 25% so far this year, were down 2% in premarket trade. The Marlboro maker, similar to other tobacco peers, has bet heavily on smoking...
Cencora raises annual profit forecast on strong demand for specialty medicines
Cencora raises annual profit forecast on strong demand for specialty medicines
Jul 31, 2024
July 31 (Reuters) - Cencora ( COR ) raised its annual profit forecast again on Wednesday, driven by strong demand for high-priced specialty medicines that treat complex diseases such as cancer. The drug distributor also beat Wall Street estimates for third-quarter profit and revenue helped by strength in its U.S. healthcare business. We see the company's fourth guidance increase of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved